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Background: Rho GTPases play important roles in cytoskeleton organization, cell cycle progression and are key
regulators of tumor progression. Strategies to modulate increased Rho GTPase activities during cancer progression
could have therapeutic potential.
Methods: We report here the characterization of a Cdc42-selective small-molecule inhibitor AZA197 for the
treatment of colon cancer that was developed based on structural information known from previously developed
compounds affecting Rho GTPase activation. We investigated the effects of AZA197 treatment on RhoA, Rac1 and
Cdc42 activities and associated molecular mechanisms in colon cancer cells in vitro. Therapeutic effects of AZA197
were examined in vivo using a xenograft mouse model of SW620 human colon cancer cells. After treatment, tumors
were excised and processed for Ki-67 staining, TUNEL assays and Western blotting to evaluate proliferative and
apoptotic effects induced by AZA197.
Results: In SW620 and HT-29 human colon cancer cells, AZA197 demonstrated selectivity for Cdc42 without
inhibition of Rac1 or RhoA GTPases from the same family. AZA197 suppressed colon cancer cell proliferation, cell
migration and invasion and increased apoptosis associated with down-regulation of the PAK1 and ERK signaling
pathways in vitro. Furthermore, systemic AZA197 treatment reduced tumor growth in vivo and significantly
increased mouse survival in SW620 tumor xenografts. Ki-67 staining and tissue TUNEL assays showed that both
inhibition of cell proliferation and induction of apoptosis associated with reduced PAK/ERK activation contributed to
the AZA197-induced therapeutic effects in vivo.
Conclusions: These data indicate the therapeutic potential of the small-molecule inhibitor AZA197 based on
targeting Cdc42 GTPase activity to modulate colorectal cancer growth.
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In recent years, the focus of cancer drug development
has shifted from conventional broad spectrum cytotoxic
drugs to therapeutics specifically targeting the molecular
mechanisms driving the development of cancer. The
Rho family proteins Rac1, Cdc42 and RhoA are small
GTP-binding proteins regulating multiple cellular pro-
cesses such as cell cytoskeleton organization, cell cycle
progression and cell migration [1]. Rho family members
act as molecular switches, cycling between an inactive,
GDP-bound form and an active, GTP-bound form that
determine the cellular functions of Rho GTPases [2].
Rho GTPase activity is modulated by differential activa-
tion of Rho GTPase regulating signaling pathways and
expression of Rho GTPase regulatory molecules such as
guanine nucleotide exchange factors (GEFs) that increase
Rho GTPase activity by promoting the release of bound
GDP [1].
Unregulated Rho GTPase activity contributes to the
development of proliferative malignancies such as colon
carcinoma influencing proliferation, apoptosis, migration
and invasion associated with cancer progression [3,4].
The discovery that Rho GTPases play important roles in
tumor development and progression raised considerable
interest in these proteins as potential targets for cancer
therapy. A number of inhibitors either targeting Rho
GTPase activity directly [1,5] or targeting regulators of
Rho GTPase activity (e.g. GEFs) have been developed
[2,6]. Although targeted drugs that inhibit Rho GTPases
and downstream signaling kinases have not yet been
widely adopted for clinical use, their potential value as
cancer therapeutics continues to drive considerable
pharmaceutical research and development [7].
Rac1 exerts tumor specific roles and is overexpressed
in many tumors [3]. Much evidence support the import-
ance of Rac1 in colorectal adenocarcinoma [8] and it has
been shown that overexpression of Rac1 in colon cancer
cells accelerates the tumorigenic process which may be
suppressed by inhibition of Rac1 expression with RNA
interference [9]. Increased RhoA expression has been
described in various human tumors including colon
cancer associated with malignant progression [10],
although Rho GTPases also seem to have a tumor
suppressive function since loss of Rho function is as-
sociated with predisposition to lymphoid cell trans-
formation [11].
Cell division control protein 42 (Cdc42) is involved in
cell cycle control and metastasis [12], and plays a role in
the regulation of cell and migration polarity [13] inhibiting
invasion by promoting epithelial polarity as well as stimu-
lating migration [6]. Cdc42 expression is up-regulated in
breast cancer [10], however loss of Cdc42 enhances liver
cancer development [14], suggesting that the multiple
roles of Cdc42 affect cancer progression in a tissue-specific manner. GTP-bound Cdc42 can interact with
multiple downstream signaling pathways, including acti-
vation of p21-activated protein kinase (PAK), which is
involved in invasion, migration and oncogenic transform-
ation [15,16]. Additionally, PAK1 expression is significant-
ly increased in colorectal cancer and closely correlates
with aggressive disease progression [17]. Moreover, Cdc42
was found to be over-expressed with high incidence in
colorectal cancer samples suggesting a potential role for
Cdc42 in tumor development [18].
In this study, we identify a highly efficient small mole-
cule anticancer agent AZA197 that specifically inhibits
Cdc42. We report that, AZA197 reduces the prolifera-
tive potential of both HT-29 colorectal cancer cells and
the highly invasive SW620 colorectal cell line associated
with decreased PAK/ERK activation. Moreover, AZA197
decreases SW620 colon cancer cell migration and inva-
sion. Studies in vivo showed that AZA197 reduces the
growth of human SW620 colon cancer xenografts and
significantly improves animal survival.
Methods
Cell lines and molecular profiling
3T3-Swiss fibroblasts (ATCC, Manassas, VA; CCL-92)
and human SW620 (ATCC, CCL-227) and HT-29 (ATCC,
HTB-38) colorectal adenocarcinoma cells were obtained
from American Type Culture Collection (ATCC) and cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM,
PAA Laboratories, Pasching, Austria) supplemented with
10% fetal calf serum (FCS; PAA Laboratories), 0.1 M non-
essential amino acids (PAA Laboratories), 100 U/ml peni-
cillin and 100 μg/ml streptomycin (culture medium). The
SW620 cell line was tested for authenticity using STR-
PCR (PowerPlex 16 HS System, Promega, Madison, WI).
Compound generation
Based on the available structural and functional informa-
tion on a small chemical compound of the National
Cancer Institute chemical database, NSC23766, targeted
against the Rho GTPase Rac1 [6] and utilizing a virtual
screening strategy using the ZINC database [19], we
generated 17 chemically diverse potential Rho GTPase-
inhibiting compound formulas, which were then synthe-
sized by SPECS (Delft, Netherlands). Subsequently, all
synthesized compounds were tested in vitro for solubility
characteristics.
Cytotoxicity assay
Lactate dehydrogenase (LDH) release in cells was assessed
with the CytoTox96 Non-Radioactive Cytotoxicity Assay
(Promega, Madison, WI) according to the manufacturer’s
instructions. Colon cancer cells and S3T3 fibroblasts were
seeded in 96-well plates, cultured for 24 h and then
incubated with 1–100 μM AZA197 for 24 h. Culture
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transferred to a 96-well plate. Samples were mixed
with freshly prepared substrate mix, incubated pro-
tected from light for 30 min at room temperature
and after addition of stop solution, absorbance was mea-
sured at 490 nm. AZA197 mediated cytotoxicity expressed
as LDH release (%) was determined as % Cytotoxicity =
[Experimental LDH release (OD490)] ÷ [Maximum LDH
release (OD490)].
Rho GTPase activation assays
Colon cancer cells were seeded in 6-well plates. Cells
were incubated with 1, 2, 5 and 10 μM AZA197 for
24 h. Rac1-, Cdc42- and RhoA-activation was then mea-
sured using G-LISA (Rac1, Cdc42 and RhoA activation
assay, colorimetric format; Cytoskeleton, Denver, CO)
according to the manufacturer’s protocol.
Guanine nucleotide-exchange assay in vitro
GEF activity was measured with the RhoGEF Exchange
Assay Biochem Kit (Cytoskeleton, Inc., Denver, CO) ac-
cording to the manufacturer’s instructions. Briefly, fluores-
cence spectroscopic analysis of N-methylanthraniloyl
(mant)-GTP incorporation into purified His-tagged Cdc42
was carried out using a Perkin Elmer EnSpire multimode
plate reader at 20°C. Exchange reaction assay mixtures
containing 20 mM Tris (pH 7.5), 50 mM NaCl, 10 mM
MgCl2, 50 μg/ml BSA, 0.8 μM mant-GTP and 1 μM
Cdc42 GTPase were prepared in the presence or absence
of 10 μM AZA197. After equilibration, assays were placed
into sample holders and fluorescence measurements taken
every 30 sec at excitation and emission wavelengths of
360 nm and 440 nm, respectively. After five readings
(150 sec), Dbs or water (control) was added to 0.8 μM and
relative mant fluorescence (λex = 360 nm, λem = 440 nm)
readings were taken for a total reaction time of 30 minutes
(1800 seconds). Experiments were performed in triplicate.
Cell proliferation assay
Human SW620 cells were seeded in 96-well plates at a
density of 1×104 cells/well in culture medium. Cells were
incubated with 1, 2, 5 or 10 μM AZA197. Cell proliferation
was determined at 24, 48 or 72 h after treatment using the
WST-1 reagent (Roche Diagnostics, Indianapolis, IN) ac-
cording to the manufacturer’s protocol [20]. Each experi-
ment was repeated three times.
FACS analysis
Tumor cells were seeded in 6-well plates and allowed to
adhere before treatment with 2, 5 or 10 μM AZA197.
Cells were then trypsinized, washed in PBS, fixed in 70%
ethanol for 1 h at 4°C and subsequently stained in PBS
supplemented with 800 μg/ml propidium iodide containing
50 μg/ml RNaseA. 104 events were analyzed on a FACScanflow cytometer (BD Biosciences) with an argon laser tuned
to 488 nm.Migration assay
Colon cancer cells (1×105 in 1 ml DMEM with 10%
FCS) were added to the top of each Boyden migration
chamber (8 μm, 12-well plate format; BD Biosciences,
Palo Alto, CA). Cells were incubated with 1, 2 and 5 μM
of AZA197. After 24 h, medium was removed and mem-
branes were washed twice with phosphate buffered sa-
line (PBS). Cells from the upper side of the membrane
were removed with cotton swabs. The membranes were
excised using a scalpel, inverted and transferred to a PBS
filled tissue culture well. Membranes were then fixed in
methanol for 10 min at −20°C. After washing in PBS,
membranes were stained with 1 μg/ml 4′-6-Diamidino-
2-phenylindole (DAPI) in PBS for 10 min at room
temperature and washed again in PBS. Membranes were
then embedded in Cityfluor (Cityfluor, Leicester, UK) on
glass slides. Representative sectors of migrated colon
cancer cells were counted under a fluorescence micro-
scope. Each experiment was performed in triplicate.Invasion assay
Colon cancer cells (5x104 in 1 ml culture medium)
were added to the top of each BioCoat Matrigel Invasion
Chamber (8 μm, 24-well plate format; BD Biosciences) in
DMEM supplemented with 0.2% FCS according to
the manufacturer’s protocol. As chemoattractant, DMEM
containing 10% FCS was added to the lower chamber.
AZA197 was then added to 1, 2 and 5 μM. After
24 h, the medium was removed and membranes were
washed twice with PBS and stained as described pre-
viously for the migration assays. Representative sectors of
invaded colon cancer cells were counted under a fluores-
cence microscope. Each experiment was performed in
triplicate.Visualization of the actin cytoskeleton and fluorescence
microscopy
Human SW620 and HT-29 cells were grown on a cham-
bered coverglass coated with fibronectin/gelatin (0.001%
fibronectin/0.2% gelatin in distilled water) in culture
medium and were then incubated with 5 or 10 μM
AZA197 for 24 h. Cells were then fixed, permeabilized, la-
belled with Atto-488 phalloidin (Sigma-Aldrich, St. Louis,
MO) and counterstained with 4′,6-Diamidino-2-Phenylin-
dole, Dihydrochloride (DAPI, Invitrogen). Fluorescence
was observed with a Nikon Eclipse 80i (Tokyo, Japan)
microscope equipped with DAPI and fluorescein-isothio-
cyanate (FITC) filters at 1,000× magnification and images
were digitally acquired.
Figure 1 Structural formula of AZA197 (N2-(4-Diethylamino-1-
methyl-butyl)-N4-[2-(1H-indol-3-yl)-ethyl]-6-methyl-pyrimidine-
2,4-diamine).
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Colon cancer cells were seeded in 100 mm plates and
incubated with 2, 5 and 10 μM AZA197 for 24 h. Cell
lysates were prepared [21,22] and 50 μg/lane were
separated by 12% SDS-PAGE prior to electrophoretic
transfer onto Hybond C super (Amersham Pharmacia
Biotech, Buckinghamshire, UK). The blots were probed
with antibodies against Cdc42, PAK1, phospho-PAK1
(Ser144)/PAK2(Ser141), ERK1/2, phospho-44/42 ERK1/2
(Thr202/Tyr204), Cyclin D1 (Cell Signaling Technology,
Danvers, MA) and α-tubulin (clone B-5-1-2, Sigma-
Aldrich) before incubation with horseradish peroxidase–
conjugated secondary antibodies (Amersham Pharmacia
Biotech). Reversible Ponceau S staining and α-tubulin stain-
ing were used as a loading control. Proteins were immuno-
detected by chemiluminescence (Supersignal-West- Femto,
Pierce, Rockford, IL), scanned using FUSION-FX7 (Vilber
Lourmat) and quantified by Fusion-CAPT-Software 16.07
(Vilber Lourmat).
Tumor model
The experiments performed in this study were approved
by the Institutional Animal Care and Use Committee at
the Vienna Medical University. Pathogen-free, male,
5 week-old athymic nu/nu (nude) mice (Charles River,
Sulzfeld Germany) were weighed, coded and divided into
experimental groups of (n = 8) at random. Mice were
anesthetized (ketamine hydrochloride/xylazine at 55/
7.5 mg/kg i.p.) and 8×106 SW620 cells/100 μl PBS were
injected s.c. into the left flank [20,21]. Eight days after
cell injection, mice received daily i.p. injections with
100 μg AZA197 in 100 μl 30% DMSO for two weeks,
control animals received 100 μl 30% DMSO/day. Tumor
volumes were calculated as length × width2÷2 using a
caliper. All animals were sacrificed on day 22 and tumor
weights were assessed.
Analysis of the effects of AZA197 in vivo
On day 22 the animals were sacrificed. Tumors were
photographed in situ following removal of the surround-
ing skin, isolated and weighed. One portion of the tissue
was processed for paraffin embedding and serial sections
were made. Sections were rehydrated, incubated in 5%
H2O2 to block endogenous peroxidase activity and anti-
gens detected with Ki-67 antibody (tumor proliferation
assay; Dako, Glostrup, Denmark) to evaluate the density
of proliferating cells [21,22]. Primary antibodies were
detected by sequential incubation with biotinylated sec-
ondary antibody (Vector Laboratories, Burlingame, CA)
and peroxidase conjugated streptavidin (Dako, Glostrup,
Denmark), developed with 3, 3′-diaminobenzidine (Vector
Laboratories), counterstained with haemalaun, dehydrated
and mounted in DPX (Merck, Darmstadt, Germany) and
digitalized images were generated.Tissue terminal deoxynucleotide transferase–mediated
dUTP nick end labeling assay
Histological analysis of nuclei exhibiting DNA fragmen-
tation was used to identify apoptotic cells in paraffin
sections of SW620 xenograft tumors by in situ terminal
deoxynucleotide transferase–mediated dUTP nick end
labeling (TUNEL) with the use of an apoptosis detection
kit (In Situ Cell Death Detection Kit, Fluorescein; Roche
Diagnostics, Indianapolis, IN) according to the manu-
facturer’s instructions. The number of TUNEL-positive
apoptotic cells was evaluated by fluorescence microscopy.
Results are expressed as relative percentage of TUNEL–
positive cells per field.
Analysis of the effects of AZA197 on survival
The survival study was set for 100 days. Mice were
treated with AZA197 (n = 6) or 30% DMSO in controls
(n = 6) and were euthanized when moribound.
Statistical analysis
Data were tested for normality using the Shapiro-Wilk
test. Groups were compared by analysis of variance
(ANOVA) and by nonparametric analysis (Wilcoxon
rank-sum test, Kruskal-Wallis test). All statistical tests
were two-sided. The overall survival curves after treat-
ment were analyzed by the Kaplan-Meier survival test.
Statistical tests were performed with the use of SPSS
software (version 20.0.2; SPSS, Chicago, IL). Data are
expressed as means ± SD. P values of < 0.05 were consid-
ered to indicate statistical significance.
Results
Identification of AZA197
An in vitro screen of small molecule inhibitors based
on modifications of NSC23766 to identify inhibitory
compound activity identified the structure (N2-(4-
Diethylamino-1-methyl-butyl)-N4-[2-(1H-indol-3-yl)-
ethyl]-6-methyl-pyrimidine-2,4-diamine), named AZA197
(Figure 1) to have strong inhibitory activity in SW620
colon cancer cells.
Cytoxicity evaluation of AZA197
The cytotoxic effect of different concentrations of AZA197
was examined by LDH release in SW620 colon cancer
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DMSO control samples were included to assess potential
cytotoxic effects of the compound solvent. In both cancer
cells and fibroblasts, a similar AZA197 toxicity profile from
1–100 μM was observed (Figure 2A for SW620 and S3T3;
Additional file 1: Figure S1A for HT-29). LDH release in
cells exposed to DMSO ranged from 12.5% in S3T3 fibro-
blasts, 12.7% in HT-29 cells to 13.2% in SW620 cells. The
LDH release profiles in all investigated cells exposed to
AZA197 up to 10 μM was comparable to solvent control
cultures. At higher AZA197 concentrations of 20, 50 and
100 μM, significantly increased levels of LDH release were
observed in all cell lines investigated with a 9-fold increase
in SW620 cells (P < 0.001) and 3-fold increases in HT-29
cells (P < 0.04) and S3T3 fibroblasts (P < 0.001) at 20 μM
(Figure 2A; Additional file 1: Figure S1A). In addition,
bright-field microscopy did not reveal any morphological
features suggestive of cytotoxicity, such as membrane
blebbing, at concentrations up to 10 μM (data not shown).
However, there was a drastic change in cell morphology at
concentrations above 10 μM which included blebbing and
evidence of nuclear fragmentation.
These data suggest that low plasma membrane damage
occurs independently of the cell type after 24 h of expos-
ure to AZA197 at concentrations up to 10 μM as evi-
denced by low intracellular LDH release. The cytotoxic
responses in both fibroblasts and cancer cells above
20 μM prompted us to use concentrations up to 10 μM
for further in vitro experiments analyzing the anti-tumor
effects of AZA197.
AZA197 treatment inhibits Cdc42 activity in colon cancer
cells
The effect of AZA197 on the activity of Rac1, Cdc42 and
RhoA GTPases was comparatively assessed in G-LISA as-
says. We first examined Rac1 activation in SW620 colon
cancer cell lysates. Treatment with 1, 2, 5 or 10 μM
AZA197 did not affect Rac1 activity (Figure 2B left panel).
AZA197 inhibited Cdc42 in a dose-dependent manner in
SW620 cells. AZA197 reduced Cdc42 activity significantly
by 56.7% (P = 0.024), 75.2% (P = 0.014), 76.0% (P = 0.035)
and 89.3% (P = 0.011) at 1, 2, 5 and 10 μM, respectively,
compared to untreated controls (Figure 2B central panel).
In contrast, RhoA activity was not significantly affected by
AZA197 treatment in SW620 cells (Figure 2 right panel).
AZA197 also dose-dependently and significantly down-
regulated Cdc42 activity in HT-29 colon cells by 18%
(1 μM, P = 0.048), 48.5% (2 μM, P = 0.011), 52.9% (5 μM,
P = 0.014) and 61.0% (10 μM, P < 0.001) as shown in
Additional file 1: Figure S1B. Similar to SW620 cells,
AZA197 treatment caused no suppression of Rac1 or
RhoA activity in HT-29 cells (Additional file 1: Figure
S1B). These results indicate that AZA197 specifically and
significantly down-regulates Cdc42 activity in the humanSW620 and HT-29 colon cancer cell lines with no effects
on Rac1 or RhoA GTPase family members.
Compound AZA197 inhibits Cdc42–GEF interaction in vitro
Since AZA197 specifically inhibits Cdc42 activity, we
hypothesized that AZA197 can act as a Cdc42–GEF
interaction-specific small-molecule inhibitor. To deter-
mine whether AZA197 is active in inhibiting the GEF-
stimulated guanine nucleotide-exchange reaction of
Cdc42, an in vitro nucleotide-exchange assay was per-
formed. The GEF activity of Dbs on Cdc42 was used as
a positive control and water as a negative control. As
shown in Figure 2C, mant fluorescence intensity in-
creased dramatically when purified Dbs domains were
added to Cdc42. Incubation with AZA197 reduced the
exchange activity of Dbs domains on Cdc42 by approxi-
mately 61% compared to the GEF activity of Dbs on
Cdc42 (P = 0.034). These data indicate that AZA197 is
able to block the nucleotide exchange of Cdc42 thereby
preventing Cdc42 activation by disrupting the inter-
action of Cdc42 with GEFs in vitro.
AZA197 suppresses cell proliferation in SW620 cells
Activation of Cdc42 stimulates many signaling cascades
that alter cellular processes such as proliferation and
migration [15]. To test whether AZA197 affects colon
cancer cell proliferation, we treated human SW620 and
HT-29 cells with different concentrations of compound
and determined the increase in mass of cellular protein
for up to 72 h. Both SW620 and HT-29 cell proliferation
were significantly reduced after 72 h incubation with 1,
2, 5 and 10 μM of compound compared to untreated
control cells (P < 0.001) (Figure 3A for SW620, and
Additional file 2: Figure S2 for HT-29). Treatment with
AZA197 suppressed SW620 and HT-29 cell proliferation
in a dose-dependent manner.
To test whether AZA197 has an influence on the cell
cycle, we treated SW620 colon cancer cells with different
compound concentrations. Treatment with AZA197
reduced cell proliferation (reduction in S and G2/M
phases, M3) and increased the number of apoptotic cells
(sub G0/G1 peak, M1) in a dose-dependent manner
(Figure 3B). These data indicate that AZA197 reduces
colon cancer cell proliferation associated with increased
apoptosis.
AZA197 reduces the migration and invasion of colon
cancer cells
Rho GTPases such as Cdc42 can also play an essential
role in tumor cell migration [23]. We therefore exam-
ined the effect of AZA197 on migration of SW620 cells
in a transwell assay. Treatment of cells with 1 μM
compound for 24 h only moderately reduced cancer cell
migration compared to untreated controls (Figure 4A).
Figure 2 Compound AZA197 promotes LDH release and inhibits Cdc42 activation. A Cytotoxicity was assessed by LDH release in SW620
colon cancer cells and S3T3 fibroblasts after 24 h exposure to AZA197 (1–100 μM). Co, untreated control; DMSO, solvent control; *, significantly
different from untreated control. B Rac1, Cdc42 and RhoA activation in SW620 colon cancer cells after incubation (24 h) with different
concentrations of compound AZA197. AZA197 suppresses Cdc42 activity in colon cancer cells in a dose-dependent manner. Means of three
independent experiments are shown. *, significantly different from untreated control. C AZA197 inhibits Cdc42 GDP/GTP exchange stimulated by
GEF. AZA197 significantly inhibits the GEF activity of Dbs on Cdc42 assessed by mant fluoresence. Experiments were performed in triplicate and
data from one representative experiment are presented. The bar chart shows the statistical analysis of relative Cdc42 GEF activity from these
measurements. *, significantly different from untreated controls.
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Figure 3 Effects of Cdc42 inhibition by AZA197 on cell proliferation in SW620 colon cancer cells. A Relative density of cancer cells up to
72 h following treatment with 1, 2, 5, and 10 μM compound AZA197 was measured using the WST-1 cell proliferation assay. AZA197 suppresses
SW620 colon cancer cell proliferation in a dose-dependent manner. Means of three independent experiments are shown. *, significantly different
from control. B Cellular DNA content was analyzed by flow cytometry after staining with propidium iodide. Representative flow cytometry
histograms showing SW620 cells treated with 2, 5 or 10 μM AZA197 for 24 h. Control cells received no treatment. AZA197 dose-dependently
reduces the number of cells in the S and G2/M phases (M3) and increases the number of cells with sub G0/G1 DNA content (M1) characteristic
of apoptosis.
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reduced cancer cell migration by 47.4 ± 8.8% (P < 0.05)
and 43.5 ± 17% (P < 0.05), respectively, compared to
untreated controls (Figure 4A). Similarly, AZA197
significantly reduced cancer cell migration in a dose-
dependent manner up to 77.1% (P < 0.024) in HT-29
colon cancer cells (Additional file 3: Figure S3A). These
results indicate a role for AZA197 in blocking Cdc42-
dependent migration of SW620 colon cancer cells.
Since migration and invasion of cancer cells are key
steps in tumor metastasis, we assessed the effects of
AZA197 on SW620 and HT-29 cancer cell invasion in a
matrigel cell invasion assay. As shown in Figure 4B, treat-
ment of SW620 cells with 1, 2 and 5 μM compound
AZA197 for 24 h significantly decreased SW620 invasion
by 61.3 ± 18%, 71.0 ± 16.6% and 83.9 ± 12.4% (P < 0.003),respectively, compared to untreated controls. Similarily,
AZA197 also significantly decreased invasion of HT-29
cells at corresponding concentrations up to 84.6%
(P < 0.005) compared to controls (Additional file 3:
Figure S3B).
Together, these results suggest that AZA197 is highly
effective in preventing SW620 and HT-29 colon cancer
cell migration and invasion in a dose-dependent manner.
Morphological and actin cytoskeleton changes in AZA197
treated colon cancer cells
Cdc42 is also crucial in the formation of filopodia, which
are important in the motility of cancer cells [24]. We
therefore investigated the effect of AZA197 on colon
cancer cell morphology with phalloidin that specifically
stains the polymerized actin cytoskeleton. In subconfluent
Figure 4 Cdc42 blockade reduces colon cancer cell migration, invasion and affects actin cytoskeleton reorganisation. A Representative
images of migrated SW620 colon cancer cells from an in vitro migration assay are shown. Colon cancer cells were treated with 1, 2 or 5 μM
AZA197 for 24 h and migrated cancer cells quantified subsequently by in vitro migration assays. Data were collected from five individual
consecutive fields of view (40x) from three replicate Boyden chambers. *, significantly different from controls. B The invasive capacity of SW620
cells was determined in matrigel invasion assays. Invaded SW620 cells were quantified from five individual consecutive fields of view (100x) from
three replicate chambers. *, significantly different from control. C Effect of AZA197 treatment on cell morphology, filopodia formation and actin
reorganization. SW620 colon cancer cells were plated on fibronectin/gelatin coated cell culture chambers and incubated with 2, 5 and 10 μM
AZA197 for 24 h. Paraformaldehyde fixed cells were stained with Atto-488 phalloidin (F-actin, green) to visualize the polymerized actin cytoskeleton
and filopodia and subsequently counterstained with DAPI (blue) and photographed (magnification, x1000). Arrows indicate filopodia. AZA197 leads to
changes in cellular morphology and suppresses filopodia formation.
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and a high number of filopodia identified (Figure 4C).
Treatment with AZA197 at 2, 5 and 10 μM caused cells to
become rounded and filopodia formation was dramatically
diminished after 24 h (Figure 4C). HT-29 cells displayed
spreading morphology and a normal filamentous actin
distribution in the surface protrusions but cells treated
with 2, 5 and 10 μM AZA197 exhibited diminished cell
spreading, a rounded cell morphology with no surface
protrusions and formation of submembranous cortical
actin (Additional file 3: Figure S3C).
These results suggest that treatment of colon cancer
cells with AZA197 results in an alteration of the actin
cytoskeleton and cell morphology in colon cancer cells
and reduces filopodia formation in SW620 cells.
The PAK1 signaling pathway is down-regulated by
AZA197 treatment in colon cancer cells
To analyze whether AZA197 affects Cdc42 protein
expression, we measured Cdc42 protein levels by Western
blot analysis. In both SW620 (Figure 5A) and HT-29
(Additional file 4: Figure S4A), Cdc42 protein levels were
not affected by treatment with different concentrations of
AZA197 suggesting that AZA197 does not affect levels of
Cdc42 protein expression.
Group I p21-activated kinases (PAKs) have been impli-
cated in colon cancer cell transformation in expression
and functional studies and are important effectors of the
small GTPase Cdc42 [25]. To analyze signaling pathways
that could mediate the effects of AZA197 on Cdc42
inhibition, we examined the activity of the downstream
effector PAK by evaluating PAK phosphorylation in
SW620 and HT-29 colon cancer cells following AZA197
treatment. Although no reduction in PAK expression
was seen (Figure 5B, left panel), PAK1/2 phosphorylation
at serine 144/141, which maintains the kinase activity of
PAKs [26], was dose-dependently significantly reduced
by 47.7 ± 6.5% (2 μM), 57.2 ± 17.3% (5 μM) and 66.2 ±
15.3% (10 μM) (P < 0.01) after treatment with 2, 5 and
10 μM AZA197 for 24 h in SW620 cells compared to
untreated cells (Figure 5B), respectively. Similarly, PAK1/2
phosphorylation was also dose-dependently and signifi-
cantly reduced up to 72.8 ± 15.8% (P < 0.014) on AZA197
treatment of HT-29 cells without influencing total PAK
protein expression (Additional file 4: Figure S4B), indi-
cating that Cdc42 inhibition blocks the PAK1 signaling
pathway in these colon cancer cells. These findings sug-
gest that AZA197 mediated Cdc42 inhibition is associated
with reduced PAK1/2 phosphorylation.
To identify further downstream Cdc42 effectors affec-
ted by AZA197 treatment, we analyzed MAPK activity
using phospho-specific antibodies. ERK activity is de-
creased by PAK1 deactivation leading to decreased cell
proliferation, migration/invasion and survival in coloncancer [27]. Our data show that Cdc42 inhibition by
AZA197 for 24 h led to a significant dose-dependent in-
hibition of phospho-ERK levels by 16.1 ± 4.6% (2 μM),
36.7 ± 12% (5 μM) and 40.2 ± 9.1% (10 μM) (P < 0.05) in
SW620 cells, whereas total ERK protein levels were not af-
fected by AZA197 treatment (Figure 5C). In HT-29 cells,
phospho-ERK levels were also significantly reduced by
29.1 ± 15.7% (2 μM), 38.2 ± 3.5% (5 μM) and 44.4 ± 6.3%
(10 μM) by AZA197 treatment (P < 0.04) compared to un-
treated cells (Additional file 4: Figure S4C). In contrast,
levels of activated p38 and JNK did not show any signifi-
cant changes in response to AZA197 treatment in colon
cancer cells (data not shown).
We then tested the effect of AZA197 on the cell cycle
regulatory protein Cyclin D1, since Rho family GTPases
have been shown to be essential for the Cyclin D1 up-
regulation associated with G1 to S phase transition. In
addition, PAK has been shown to play a role in upregula-
tion of Cyclin D1 involving activation of ERK kinase [28].
In SW620 colon cancer cells treated with 2, 5, and 10 μM
AZA197 for 24 h, Cyclin D1 protein expression decreased
significantly by 16.8 ± 2.2% (2 μM), 18.6 ± 4.5% (5 μM)
and 37.1 ± 14.1% (10 μM) (P < 0.05) compared to un-
treated controls as shown in Figure 5D. In HT-29 cells,
Cyclin D1 protein expression was significantly reduced
when treated with 5 μM (22 ± 5.5% reduction) and 10 μM
(20.8 ± 9.9% reduction) (P < 0.049) but not with 2 μM
AZA197 (Additional file 4: Figure S4D).
These results suggest targeting Cdc42 with the small
molecule inhibitor AZA197 in colon cancer cells can
effectively modulate PAK/ERK signaling interfering
with Cyclin D1 expression to affect colon cancer cell
proliferation.
AZA197 suppresses primary colon cancer growth and
prolongs animal survival
To analyze whether treatment with AZA197 can modu-
late tumor growth in vivo, we treated mice bearing
human SW620 colon cancer xenografts with AZA197 or
vehicle as controls. To assess treatment modalities in vivo,
we initially assessed AZA197 stability in vitro (data not
shown) and cycled treatment daily for two weeks to
guarantee continuous delivery of the compound. At the
beginning of treatment on day 8, mice developed tumor
xenografts of comparable size. On day 22, the mean tumor
weight was significantly (P = 0.006) reduced in mice
treated with AZA197 (676.7 ± 106 mg) compared to con-
trol mice (968 ± 208 mg) and treatment was well tolerated
(Figure 6A). To compare the proliferation and apoptotic
rate of untreated tumors and tumors treated with
AZA197, tumor sections were stained for expression of
Ki-67 and DNA fragmentation by TUNEL assays, respect-
ively. In accordance with the tumor weight reduction find-
ings, treatment with AZA197 decreased the number of
Figure 5 Analysis of AZA197-signal transduction effectors in SW620 colon cancer cells. A Cdc42 levels were not changed in SW620 cells
treated with AZA197 compared to untreated cells. Means of 3 independent experiments are shown. B,C Analysis of PAK1 (B) and ERK (C)
phosphorylation in SW620 colon cancer cells after AZA197 treatment. Representative Western blot images and quantification of immunoblots
stained with PAK1, phospho-PAK1/2 (pPAK) and ERK, phospho-ERK (pERK) antibodies before and after treatment with 2, 5, and 10 μM AZA197 for
24 h. Cdc42 blockade reduces PAK1 and ERK phosphorylation in SW620 cells (mean of 3 independent experiments) without affecting total protein
levels. *, significantly different from control. D Analysis of CyclinD1 expression in SW620 colon cancer cells following AZA197 treatment. Represen-
tative Western blot images and quantification of immunoblots stained with CyclinD1 antibody before and after treatment with 2, 5, and 10 μM
AZA197 for 24 h. CyclinD1 levels were reduced following AZA197 treatment of SW620 cells (mean of three independent experiments). LC, loading
control; SP, specific protein; *, significantly different from control.
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randomly selected microscopic fields by 27.4 ± 14.2%
(P = 0.046) in AZA197-treated tumors, suggesting an anti-
proliferative effect for AZA197 (Figure 6B). Moreover,AZA197-treated tumors showed increased numbers of
apoptotic cells as assessed by positive staining for TUNEL
compared with untreated controls. Based on the counting
of randomly selected microscopic fields, the number of
Figure 6 (See legend on next page.)
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Figure 6 Cdc42 blockade by AZA197 suppresses tumor growth and prolongs animal survival. A Left panel: representative images of
human SW620 tumor xenografts on day 22 from mice treated with solvent (Control) or 100 μg/day AZA197 (AZA197 d22) (bar = 10 mm). Right
panel: AZA197 significantly suppresses tumor weight of human colon cancer xenografts in mice. Data are shown as mean tumor weights on day
22. *, significantly different from control on day 22 (P = 0.006). B Effect of AZA197 on proliferation in SW620 xenografts. Left panel: representative
immunohistochemistry images of tumor tissue sections from mice treated with solvent (Control) or 100 μg/day AZA197 on day 22 stained with
Ki-67 antibody (bar = 200 μm). Right panel: Quantitative histomorphometric analysis of Ki-67-positive, proliferating tumor cells. *, significantly
different from control (P = 0.046). C Effect of AZA197 on apoptosis in SW620 xenografts. TUNEL labeling of cells undergoing DNA fragmentation:
Left panel: representative images of tumor tissue sections from mice treated with solvent (Control) or 100 μg/day AZA197 on day 22 (bar = 50 μm).
Right panel: Quantitative histomorphometric analysis of TUNEL-positive, apoptotic tumor cells. *, significantly different from control (P = 0.035). D
Analysis of total Cdc42 protein expression and levels of PAK1 and ERK phosphorylation in SW620 colon cancer tissue on day 22 from mice treated with
solvent (Control) or 100 μg/day AZA197 (AZA197 d22). Representative Western blot images and quantification of immunoblots stained with Cdc42,
PAK1 and phospho-PAK1/2 (pPAK), ERK and phospho-ERK antibodies. Cdc42 blockade by AZA197 reduces PAK1/2 and ERK phosphorylation in SW620
tumor tissue. *, significantly different from control. E Effect of AZA197 treatment on animal survival in SW620 colon cancer bearing mice. Kaplan-Meier
survival curves for controls and AZA197 treated mice. AZA197 significantly prolongs animal survival.*, significantly different to control (P = 0.042).
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from controls to AZA197-treated tumors (Figure 6C).
Western blotting of isolated tumor tissue indicated
that AZA197 treatment does not change Cdc42 and
total PAK and ERK expression. Phospho-PAK1 ex-
pression in tumors treated with AZA197 was signifi-
cantly reduced by 48.5 ± 11.4% (P = 0.027) compared
to untreated controls (Figure 6D). Similarly, in tumors
treated with AZA197, phospho-ERK levels decreased
significantly by 59.2 ± 17.1% (P = 0.003) compared to
untreated controls (Figure 6D). These data show that the
PAK-ERK signaling pathway is a downstream target of the
small molecule inhibitor AZA197 in SW620 colon cancer
tissue confirming our findings in vitro.
In mice bearing colon cancer xenografts, the median
time to death in the control group was 53 days and all
mice died between 45 and 92 days after tumor cell graft-
ing. However, survival was significantly increased in
mice following AZA197 treatment compared to control
mice (P = 0.042) and the median time to death was
69 days. On day 100 (at the end of the experiment), all
animals in the control group were deceased whereas
50% of AZA197-treated mice were still alive (Figure 6E).
Control mice that died on days 45, 57 and 58 had tumor
weights of 3455, 4582 and 4810 mg, respectively,
whereas mice in the AZA197 treatment group at com-
parable time points at days 47 and 64 had tumors of
2897 and 3768 mg, respectively, showing that AZA197
treatment results in decreased tumor weight even after
the end of treatment on day 22. Together, these data
indicate that AZA197 slows primary tumor growth of
human SW620 colon cancer xenografts in mice and
improves animal survival.
Discussion
Significant progress has been achieved in deciphering the
molecular events associated with the onset of colorectal
cancer and molecular analyses are becoming mainstream
in planning the management of advanced colorectalcancer with tailored therapies. Although new, targeted
therapies have become available in recent years, some
patients are resistant to the clinical benefits of these
agents which have only a modest impact on disease. In
advanced colorectal cancer patients with mutated KRAS,
for example, targeted therapies have provided no benefit
showing a clear need to establish new therapeutic strat-
egies [29-31].
Although a recent study has shown that a strong
decrease in Cdc42 and Rac1 activity in combination with
ROCK inhibition is clearly associated with increased
colon cancer invasiveness [32], data from previous stud-
ies addressing the molecular mechanisms underlying
colon cancer progression suggested that Rho family
members including Cdc42 may play a critical role in
promoting colon cancer progression [15]. Cdc42 is over-
expressed in a number of human cancers and may be
involved in the promotion of tumorigenesis and Cdc42
activity has been implicated in the invasive phenotype
which characterizes tumor metastasis [15]. Analyses of
human colorectal cancer specimens identified a high
incidence of Cdc42 overexpression [18] and showed that
presence of Cdc42 target proteins could be readily de-
tected in tumors from human colorectal cancer patients,
providing a screening tool for both enrolling patients in
future clinical trials and evaluating the outcome of
such trials. In the same study, Cdc42 overexpression
in SW620 cancer cells down-regulated the potential
tumor suppressor gene ID4 [18], further indicating
that Cdc42 may play a role in the development of
colon cancer and is a suitable target for intervention
in patients with this disease.
Based on these findings, we hypothesized that in-
hibition of Cdc42 might be effective for the treatment
of colorectal cancer. We therefore designed the small
molecule Cdc42 inhibitor AZA197 and show that inhib-
ition of Cdc42 activity with AZA197 acts to reduce tumor
growth and significantly improve animal survival in
SW620 cells which are a model of KRAS mutant colon
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that inhibition of cell proliferation and induction of
apoptosis were the main mechanisms by which AZA197
exerts antitumor effects.
Other Cdc42 modulators such as CID-2950007 [34],
secramine [35] and ZCL278 [36] inhibit Cdc42 by differ-
ent mechanisms. ZCL278 targets the interaction of
Cdc42 with a specific Cdc42-GEF intersectin [36], while
secramine inhibits Cdc42 activation in a Rho GDI-
dependent manner [35]. The Rac-inhibitor NSC23766
inhibits Rac activation by blocking only some of the
GEFs that activate Rac1 [6], highlighting the complexity
of cellular pathways regulating the activation status of
RhoGTPases. In general, many of the described RhoGT-
Pase inhibitors lack specificity. Thus it is possible, that
compound screening of modifications of a known inhi-
bitor, such as with the Rac1-GEF inhibitor NSC23766
presented here, can result in the identification of an in-
hibitor that could affect the activation status of another
RhoGTPase which was not predicted by mechanistic in
silico analysis of binding to the RhoGTPase structure.
Since the function of RhoGTPases, including Cdc42, is
controlled by multiple upstream regulators and down-
stream effectors which could be affected by compounds,
the efficacy of an inhibitor may depend on the cellular
context and effectors expressed. In this context, it is
important to mention that, although our data indicate
that AZA197 inhibits Cdc42–GEF interaction in vitro,
analysis of the crystal structure of Cdc42 bound to
AZA197 would be necessary to confirm interaction with
the region where GEFs associate with Cdc42. Such data
would also allow prediction of compound efficacy based
on cell type specific expression of GEFs. To analyze
AZA197 specificity for Cdc42 inhibition, we tested the
effects of AZA197 on inhibition of the Rho GTPase
family members Rac and Rho, which also play a role in
colon cancer. Studies of the Rho GTPase family member
Rac in SW620 cells, genetically modified to either over-
express or lack Rac1 expression, suggested that Rac1
also plays a major role in colorectal adenocarcinoma
progression [9]. Rac proteins are overexpressed in vari-
ous tumors and Rac-dependent cell signaling has been
shown to be important for malignant transformation
[12]. Our data show that AZA197 does not inhibit
Rac activity in SW620 colon cancers. Thus, inhibition
of Cdc42-activity alone without affecting Rac-activity
could lead to a potent suppression of colon cancer
growth and increased survival rates. However, since
the Rho GTPases, including Cdc42, are involved in
the regulation of many normal cellular functions in a
variety of cell types, it is possible that toxicity will
limit inhibition of RhoGTPase activity in patients,
although inhibition of Cdc42 by AZA197 was well
tolerated in the tested context.Like Cdc42 and Rac, high protein expression levels of
the Rho GTPase RhoA appears to be a frequent event in
different types of human tumors, including colon cancer
[10] and increased RhoA activity correlates with poor
prognosis and recurrence in hepatocellular carcinoma
[37]. Even though RhoA may be involved in colon
cancer progression, our data reveal that RhoA is not
suppressed by AZA197 treatment and thus is not a
target for AZA197. Unlike RhoA, RhoB is often down-
regulated in human tumors and expression inversely cor-
relates with tumor aggressiveness. This can be explained
by its potential role as a tumor suppressor and RhoB levels
are attenuated commonly during malignant progression
[38]. In line with this, we did not detect active RhoB in
control or AZA197 treated colon cancer cells, consist-
ent with the general aggressive behavior of these cells
(data not shown).
Cdc42 plays an important role in cytoskeleton
organization and reducing Cdc42 activity with AZA197
resulted in a loss of filopodia formation and significantly
reduced colon cancer cell cell migration and invasion
capacity. Data from patients showing that Cdc42 is over-
expressed with high incidence in colorectal adenocarcin-
oma biopsies [18] and the findings in this study, support
the notion that Cdc42 inhibition could be used as a
therapeutic strategy to fight colorectal cancer. This is
supported by a report suggesting that active Cdc42 can
enhance colorectal cancer cell migration and invasion
[39]. Furthermore, expression of constitutively active
Cdc42 significantly increased filopodia formation and
cell spread in colorectal cancer cells, which is in line
with our findings [39]. Moreover, the finding that inhib-
ition of Cdc42 results in loss of elongated, mesenchymal
morphology [40], which we also observed following
AZA197 treatment, further strengthens the function of
AZA197 as a Cdc42 inhibitor and the tumor promoting
role of Cdc42 in colon cancer. However, activation of
Cdc42 can induce cell adhesion [41] and it has been
recently shown that activated Cdc42 increases SW480
colorectal cancer cell adhesion, migration and invasion
[39]. It is therefore possible that AZA197 inhibition of
Cdc42 also affects cell adhesion in addition to impair-
ment of colon cancer cell proliferation, migration and
invasion.
PAK1 is a main downstream effector of the Rho
GTPases Rac1 and Cdc42 [42]. Overexpression of PAK1
has been detected in colorectal cancer and PAK1 expres-
sion closely correlated with the aggressive progression of
colorectal cancer [17,43]. A recent study showed that
PAK1-dependent MAPK pathway activation is required
for colorectal cancer cell proliferation. PAK1 knockdown
decreased proliferation and delayed the G1/S cell-cycle
transition and increased apoptosis in vivo and in vitro
[44]. In line with these findings, we observed significant
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associated with decreased proliferation following AZA197
treatment in SW620 cancer cells in vitro and in SW620
cancer tissue. Additionally, Cdc42 inhibition by AZA197
resulted in increased apoptosis in vivo and in vitro. More-
over, colon cancer cells overexpressing PAK1 have higher
migration rates, whereas down-regulation of PAK1 signifi-
cantly reduces cell migration [17]. This is in line with our
findings of reduced SW620 cancer cell migration follow-
ing AZA197 treatment. Furthermore, the ERK-dependent
pathway is required in PAK1-mediated colon cancer cell
migration and invasion [17]. Consequently, the observed
down-regulation of the Cdc42-PAK1 signaling pathway
could therefore constitute the major effector pathway of
AZA197 in colon cancer.
However, there are some limitations to the interpret-
ation of the potential effects of AZA197 on cell prolifer-
ation and cancer cell migration and invasion in this
study. Our data in SW620 cells suggest that AZA197
may impact cancer cell viability at concentrations that
inhibit Cdc42, cell proliferation and actin cytoskeletal
changes in SW620 cells. Impaired cell viability may be
expected because in addition to regulation of cell migra-
tion and invasion, Cdc42 and the downstream signaling
mediator PAK1 have also been implicated in regulation
of the cell cycle, thereby affecting cell survival and
apoptosis [1,12,28], which is in line with our findings in
SW620 cells. In contrast, in HT-29 cancer cells, viability
and proliferation were not affected by AZA197 at
concentrations that significantly inhibit Cdc42 activity as
well as cancer cell migration and invasion. Moreover, at
concentrations that inhibit Cdc42-mediated mor-
phological changes, we do not see significant effects of
AZA197 on cell viability in HT-29 cells. These findings
rather suggest cell line-dependent variations in AZA197
effects than a general unspecific effect of AZA197 on
cell viability. Importantly, our data also demonstrate that
AZA197 does not affect the viability of fibroblasts at
effective concentrations indicating AZA197 to be a
viable, anti-cancer therapeutic agent with only minor
toxicity to normal cells. Our studies in athymic nude
mice revealed no changes in body weight or gross indi-
cations of toxicity (data not shown). It may therefore be
expected that use of AZA197 as an anti-cancer thera-
peutic in colon cancer would result in a varying response
to the compound depending on the specific genetics of
the cancer cells.
Conclusions
In summary, the present study describes a novel small
molecule inhibitor which can be used to effectively
inhibit the Rho GTPase Cdc42 in the treatment of
KRAS mutant colorectal cancers. We provide evidence
that Cdc42 inhibition by AZA197 treatment suppressesproliferative and pro-survival signaling pathways via
PAK1-ERK signaling and reduces colon cancer cell migra-
tion and invasion. Furthermore, we show that systemic
AZA197 treatment in vivo reduces primary tumor growth
and prolongs survival in KRAS mutant colon cancer
xenograft-bearing mice. We propose that therapy target-
ing Rho GTPase Cdc42 signaling pathways may be effect-
ive for treatment of patients with advanced colon cancer
overexpressing Cdc42 and particularly those with KRAS-
mutant disease.Additional files
Additional file 1: Figure S1. Compound AZA197 promotes LDH
release and inhibits Cdc42 activation. A Cytotoxicity was assessed by LDH
release in HT-29 colon cancer cells after 24 h exposure to AZA197
(1–100 μM). Co, untreated control; DMSO, solvent control; *, significantly
different from untreated control. B Rac1, Cdc42 and RhoA activation in
HT-29 colon cancer cells after incubation (24 h) with different concentra-
tions of compound AZA197. AZA197 suppresses Cdc42 activity in colon
cancer cells in a dose-dependent manner. Means of three independent
experiments are shown. *, significantly different from untreated control.
Additional file 2: Figure S2. Effects of Cdc42 inhibition by AZA197 on
cell proliferation in HT-29 colon cancer cells. A Relative density of cancer
cells up to 72 h following treatment with 1, 2, 5 and 10 μM AZA197 was
measured using the WST-1 cell proliferation assay. AZA197 suppresses
HT-29 colon cancer cell proliferation in a dose-dependent manner. Means
of three independent experiments are shown. *, significantly different
from control.
Additional file 3: Figure S3. Cdc42 blockade reduces colon cancer cell
migration, invasion and affects actin cytoskeleton reorganization. A
Representative images of migrated HT-29 colon cancer cells from an
in vitro migration assay are shown. Colon cancer cells were treated with
1, 2 or 5 μM AZA197 for 24 h and migrated cancer cells quantified
subsequently by in vitro migration assays. Data were collected from five
individual consecutive fields of view (40x) from three replicate Boyden
chambers. *, significantly different from control. B The invasive capacity
of HT-29 cells was determined in matrigel invasion assays. Invaded HT-29
cells were quantified from five individual consecutive fields of view (100x)
from three replicate chambers. *, significantly different from control.
C Effect of AZA197 treatment on cell morphology, filopodia formation
and actin reorganization. HT-29 colon cancer cells were plated on fibro-
nectin/gelatin coated cell culture chambers and incubated with 2, 5 and
10 μM AZA197 for 24 h. Paraformaldehyde fixed cells were stained with
Atto-488 phalloidin (F-actin, green) to visualize the polymerized actin
cytoskeleton and filopodia and subsequently counterstained with DAPI
(blue) and photographed (magnification x1,000). AZA197 leads to
changes in cellular morphology.
Additional file 4: Figure S4. Analysis of AZA197-signal transduction
effectors in HT-29 colon cancer cells. A Cdc42 levels were not changed in
HT-29 cells treated with AZA197 compared to untreated cells. Means of 3
independent experiments are shown. B, C Analysis of PAK1 (B) and ERK
(C) phosphorylation in HT-29 colon cancer cells after AZA197 treatment.
Representative Western blot images and quantification of immunoblots
stained with PAK1, phospho-PAK1/2 (pPAK), ERK and phospho-ERK (pERK)
antibodies before and after treatment with 2, 5 and 10 μM AZA197 for 24 h.
Cdc42 blockade reduces PAK1 and ERK phosphorylation in HT-29 cells
(mean of 3 independent experiments) without affecting total protein levels.
*, significantly different from control. D Analysis of CyclinD1 expression in
HT-29 colon cancer cells following AZA197 treatment. Representative
Western blot images and quantification of immunoblots stained with Cyclin
D1 antibody before and after treatment with 2, 5 and 10 μM AZA197 for
24 h. Cyclin D1 levels were reduced following AZA197 treatment of HT-29
cells (mean of three independent experiments). *, significantly different from
control. SP, specific protein; LC, loading control.
Zins et al. Journal of Translational Medicine 2013, 11:295 Page 15 of 16
http://www.translational-medicine.com/content/11/1/295Abbreviations
GEFs: Guanine nucleotide exchange factors; Cdc42: Cell division control
protein 42; PAK: p21-activated protein kinase; ERK: Extracellular-signal
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